18 results about "Hepatocyte growth factor" patented technology

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp) / kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The invention discloses a linear poly (beta-amino ester) compound loaded with hepatocyte growth factors as well as a preparation method and application of the linear poly (beta-amino ester) compound, and belongs to the technical field of biological medicines. The compound is obtained by self-assembly of linear poly beta-amino ester DD90-C12-DMEN and HGF mRNA in a buffer solution, the compound is suitable for aerosol inhalation delivery, higher mRNA transfection efficiency is obtained in lung-related epithelial / stromal cells, macrophages and other cells difficult to transfect, and particularly, the compound shows remarkable transfection advantages on the macrophages.

Provided herein are genetically modified cells such as pluripotent stem cells and mesenchymal stem cells and methods of making the same. The gene editing strategies of the present disclosure enable high expression of transgenes in genetically modified cells.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and / or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.

The invention discloses a culture medium, a culture method and application of mouse hepatic sinus vascular endothelial cells. Belongs to the technical field of cell culture. Components of the culture medium are optimized, in the aspect of growth factors, conventional VEGF / bFGF combination is broken through, liver cell growth factors and platelet-derived growth factors are creatively compounded with the growth factors, cell proliferation is driven, and liver-derived specific phenotypes and functional integrity of LSEC are maintained. An anti-oxidation system composed of N-acetylcysteine, ascorbic acid, alpha-tocopherol and riboflavin is constructed, active oxygen is synergistically removed through multiple mechanisms, and the activity and stability of cells in long-term culture are improved. Sodium pyruvate is additionally supplemented as an energy substrate, and taurine, glycine and other specific amino acids simulating the intrahepatic microenvironment provide energy and nutritional support for cell proliferation, and promote function maintenance. The efficient and stable in-vitro amplification and function maintenance of the LSEC are realized, and a solid foundation is laid for constructing a high-fidelity LSEC model.

The invention relates to a molecular marker for diagnosis, prognosis evaluation and treatment of cardiac fibrosis, and belongs to the technical field of biological medicines. The invention provides a molecular marker capable of diagnosing cardiac fibrosis, evaluating the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular diseases accompanied with cardiac fibrosis or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises a hepatocyte growth factor. Research finds that the HGF is remarkably increased in plasma of a patient with cardiac fibrosis, and the plasma HGF level of a patient with aortic valve stenosis is also remarkably increased before an operation, so that the HGF can be used for diagnosing cardiac fibrosis and evaluating the severity of cardiac fibrosis. Researches find that timely transient increase of the HGF in plasma of a patient with acute myocardial infarction is significantly related to good prognosis, and continuous low-level increase, continuous high-level increase, recurrence and delayed increase of the HGF are significantly related to poor prognosis, so that the HGF can be used for evaluating prognosis of acute myocardial infarction.

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

This disclosure relates to a method for establishing a HepaRG-based differentiated liver 3D microsphere model and its applications. Specifically, this disclosure provides a chemically defined differentiation medium formulation that does not require DMSO and contains hepatocyte growth factor, dexamethasone, and hepatoprotectin M. Using this medium, HepaRG cells can be efficiently induced to form compact, long-lived 3D microspheres in ultra-low adsorption 96-well plates or in conjunction with high-throughput 3D printing technology. After differentiation and maturation, the model can stably express hepatocyte markers, key drug-metabolizing enzymes, and nuclear receptors at high levels. The liver 3D microsphere model established by this disclosure can effectively simulate hepatocyte function in vivo and is suitable for high-throughput drug hepatotoxicity screening. The results show a high degree of consistency with clinical hepatotoxicity data, and it has important application value in the field of drug safety evaluation.

This invention discloses a highly active duck embryo liver primary cell and its low-cost preparation method and applications. The preparation method includes: obtaining and pretreatment of duck embryo liver tissue, separation by complex enzyme digestion, preparation of cell suspension, primary cell culture, and maintenance of cell viability. The core of this method lies in the gentle digestion using a complex digestion solution composed of collagenase I, trypsin, and DNase I in specific weight ratios, followed by culture in a well-defined, non-commercial growth factor-free complete culture medium. This complete culture medium contains synergistic components such as DMEM / F12, fetal bovine serum, epidermal growth factor, hepatocyte growth factor, and an insulin-transferrin-selenium mixture. The duck embryo liver primary cells prepared by this invention exhibit high yield, high viability, and excellent liver-specific function, and can maintain their activity and function well after passage and cryopreservation.

The present invention relates to an adeno-associated virus (AAV) vector optimized for intrathecal administration into which a hepatocyte growth factor gene is introduced. The AAV vector of the present invention and AAV particles produced through the vector have excellent productivity of AAV particles comprising a hepatocyte growth factor gene, and when administered intrathecally to a mammal, the expression efficiency of hepatocyte growth factor is also very high. Therefore, the AAV vector of the present invention and the AAV particles induce the expression of hepatocyte growth factor protein when administered intrathecally, and thus can be effectively used in the prevention or treatment of related diseases.

The application provides a method for long-term in-vitro culture and expansion of primary hepatocytes and application thereof. The method for in-vitro culture and expansion of primary hepatocytes comprises using a culture medium containing interleukin-22 (IL-22), combined with hepatocyte growth factor (HGF) and / or epidermal growth factor (EGF) to induce primary hepatocytes to prepare proliferative liver precursor cells. The application combines interleukin-22 (IL-22), hepatocyte growth factor (HGF) and / or epidermal growth factor (EGF) to induce in-vitro mass expansion of primary hepatocytes, and through the method, mature-like hepatocytes with a gene expression profile extremely similar to that of primary hepatocytes and perfect functions can be obtained, and the hepatocytes expanded by the method have good in-vivo therapeutic effects.

The invention discloses a mesenchymal stem cell suitable for osteoarthritis diseases and cultured by adopting an optimized medicine combination, and belongs to the technical field of stem cells. The technical problems to be solved are that in the existing mesenchymal stem cell culture process, stemness loss, differentiation potential weakening, multiplication capacity reduction and the like are easily caused by increase of culture generations. According to the key point of the technical scheme, the pharmaceutical composition is provided and comprises betamethasone dipropionate, betamethasone sodium phosphate, interleukin-10 (IL-10) and a hepatocyte growth factor (HGF), by adding the composition into a mesenchymal stem cell culture medium, the technical problems of stemness loss, differentiation potential weakening, multiplication capacity reduction and the like caused by increase of culture generations can be effectively solved.

A molecular marker for diagnosing, prognosis, evaluating, and treating cardiac fibrosis and belongs to the technical field of biomedicine. The present disclosure provides a molecular marker capable of diagnosing cardiac fibrosis, assessing the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular disease with cardiac fibrosis, or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises hepatocyte growth factor. It has been found that HGF is significantly elevated in the plasma of patients with cardiac fibrosis and also considerably elevated in patients with aortic stenosis before surgery. Therefore, HGF can be used to diagnose cardiac fibrosis and evaluate its severity.

This invention relates to an in vitro maturation culture medium for giant panda oocytes and its application, belonging to the field of biotechnology. The invention discloses an in vitro maturation culture medium for giant panda oocytes, which simultaneously adds the following three paracrine factors to the basal culture medium: adenosine diphosphate riboylation factor 6 (ARF6); ciliary neurotrophic factor (CNTF); and hepatocyte growth factor (HGF). The invention also provides the application of the aforementioned in vitro maturation culture medium for giant panda oocytes, specifically for the in vitro maturation culture of giant panda oocytes. This invention effectively addresses the shortcomings of existing in vitro oocyte maturation technologies, significantly improves oocyte maturation quality, is simple to operate, and has high safety, providing a key technological reserve for assisted reproduction in giant pandas.